Evidence map›Paper›PMID 41860657›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Prognostic significance of tumor budding and residual viable tumor volume in post-neoadjuvant resection specimens of locally advanced cervical cancer.

Peiye Shen, Jing Ye, Han Ning Yee, Lu Zhang, Xiaoxiao Hu, Xiaoran Long, Premalatawati Krishna, Yen Ching Yeo, Huaiwu Lu, Wen Di and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peiye Shen *State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing Ye *State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Han Ning Yee *Department of Pathology and Laboratory Medicine, Kandang Kerbau Women's and Children's Hospital, Singapore, Singapore.
Lu ZhangState Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoxiao HuState Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoran LongState Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Premalatawati KrishnaDepartment of Pathology and Laboratory Medicine, Kandang Kerbau Women's and Children's Hospital, Singapore, Singapore.
Yen Ching YeoDepartment of Pathology and Laboratory Medicine, Kandang Kerbau Women's and Children's Hospital, Singapore, Singapore.
Huaiwu LuDepartment of Gynecologic Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Wen DiState Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ruoyu ShiDepartment of Pathology, National University Hospital Singapore, Singapore, Singapore. shi_ruoyu@nuhs.edu.sg.
Xia YinState Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China. yinxia2@aliyun.com.ORCID http://orcid.org/0000-0003-4901-7068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a leading cause of cancer-related mortality in women, with locally advanced disease posing significant therapeutic challenges. This study evaluated the prognostic significance of tumor budding (TB) and residual viable tumor (RVT) among 101 patients with locally advanced cervical cancer (LACC) treated with neoadjuvant chemotherapy (NACT) followed by radical surgery. Using the modified International Tumor Budding Consensus Conference (ITBCC) criteria, we found that the TB-positive subgroup had significantly worse overall survival (OS) in univariate analysis (HR = 8.57; P < 0.001). Both TB-positive status (HR = 2.96; P = 0.045) and RVT > 10% (HR = 4.25; P = 0.024) were significant predictors of poorer recurrence-free survival (RFS). Multivariate analysis confirmed that RVT > 10% (HR = 3.66; P = 0.048) was an independent prognostic factor for RFS. These results support integrating TB and RVT assessment into the standard pathological evaluation of post-NACT surgical resection specimens from LACC patients.

Indexed as

Cervical cancerNeoadjuvant chemotherapyResidual viable tumorTumor budding

Identifiers

PMID41860657

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.